Published in Chest on December 01, 2004
COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res (2011) 1.43
MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Respir Res (2005) 1.37
Pulmonary-intestinal cross-talk in mucosal inflammatory disease. Mucosal Immunol (2011) 1.26
Pulmonary epithelium, cigarette smoke, and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2007) 1.15
Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol (2010) 1.15
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis (2007) 1.15
Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2007) 1.14
Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet (2010) 1.08
Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther (2008) 0.99
Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One (2013) 0.97
Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study. BMC Pulm Med (2010) 0.95
CD8+ T cells contribute to macrophage accumulation and airspace enlargement following repeated irritant exposure. Exp Mol Pathol (2007) 0.94
Effects of woodsmoke exposure on airway inflammation in rural Guatemalan women. PLoS One (2014) 0.94
Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency. Respir Res (2011) 0.92
IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice. J Immunol (2009) 0.92
Chlamydophila spp. infection in horses with recurrent airway obstruction: similarities to human chronic obstructive disease. Respir Res (2008) 0.92
The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J (2011) 0.91
Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo. J Allergy Clin Immunol (2008) 0.88
Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med (2008) 0.86
DNA sequence variations of metalloproteinases: their role in asthma and COPD. Postgrad Med J (2007) 0.85
Trachea epithelium as a "canary" for cigarette smoking-induced biologic phenotype of the small airway epithelium. Clin Transl Sci (2009) 0.84
Influence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPD. Mediators Inflamm (2013) 0.83
Human T cells stimulate fibroblast-mediated degradation of extracellular matrix in vitro. Clin Exp Immunol (2007) 0.83
Genetic polymorphism of matrix metalloproteinase family and chronic obstructive pulmonary disease susceptibility: a meta-analysis. Sci Rep (2013) 0.81
A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respir Res (2009) 0.81
Protease-antiprotease imbalance in inflammatory diseases in the lung. Chest (2005) 0.80
Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection. Respir Res (2015) 0.80
Specific IgA and metalloproteinase activity in bronchial secretions from stable chronic obstructive pulmonary disease patients colonized by Haemophilus influenzae. Respir Res (2012) 0.80
The effect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res (2009) 0.79
Variability in proteinase-antiproteinase balance, nutritional status, and quality of life in stable chronic obstructive pulmonary disease due to tobacco and nontobacco etiology. Lung India (2016) 0.79
Budesonide ameliorates lung function of the cigarette smoke-exposed rats through reducing matrix metalloproteinase-1 content. Int J Clin Exp Pathol (2015) 0.78
Increase in net activity of serine proteinases but not gelatinases after local endotoxin exposure in the peripheral airways of healthy subjects. PLoS One (2013) 0.77
ADAM17 mediates MMP9 expression in lung epithelial cells. PLoS One (2013) 0.77
Association of matrix metalloproteinase 8 genetic polymorphisms with bronchial asthma in a Japanese population. Allergy Rhinol (Providence) (2013) 0.77
Possible role of Krüppel-like factor 5 in the remodeling of small airways and pulmonary vessels in chronic obstructive pulmonary disease. Respir Res (2016) 0.76
Collagenolytic matrix metalloproteinases in chronic obstructive lung disease and cancer. Cancers (Basel) (2015) 0.76
Targeted Disruption of Ig-Hepta/Gpr116 Causes Emphysema-like Symptoms That Are Associated with Alveolar Macrophage Activation. J Biol Chem (2015) 0.76
Distinct emphysema subtypes defined by quantitative CT analysis are associated with specific pulmonary matrix metalloproteinases. Respir Res (2016) 0.75
Theaflavins extracted from black tea inhibit airway mucous hypersecretion induced by cigarette smoke in rats. Inflammation (2012) 0.75
Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO. PLoS One (2015) 0.75
Inflammatory bowel disease and airway diseases. World J Gastroenterol (2016) 0.75
Original Research: Extract of Bambusae Caulis in Taeniam inhibits cigarette smoke-induced pulmonary and intestinal inflammation. Exp Biol Med (Maywood) (2016) 0.75
The Relationship between Airway Inflammation and Exacerbation in Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2017) 0.75
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
Systemic effects of smoking. Chest (2007) 3.63
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest (2003) 2.90
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80
Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem (2003) 2.63
Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci U S A (2006) 2.51
Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med (2002) 2.32
Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. Chest (2014) 2.27
Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur Respir J (2013) 2.20
Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A (2004) 2.19
Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study. Lung Cancer (2006) 2.07
Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J (2013) 2.05
Inaccuracy of estimating peak work rate from six-minute walk distance in patients with COPD. COPD (2012) 1.98
Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med (2005) 1.81
Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.79
Increased granzyme A expression in type II pneumocytes of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.76
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72
Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol (2002) 1.71
Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med (2013) 1.67
An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63
Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition (2003) 1.60
Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. Bone (2012) 1.56
Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med (2005) 1.54
Leptin as regulator of pulmonary immune responses: involvement in respiratory diseases. Pulm Pharmacol Ther (2013) 1.54
Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J (2004) 1.53
The role of leptin in the development of pulmonary neutrophilia in infection and acute lung injury. Crit Care Med (2014) 1.49
Critical view on diagnosing muscle wasting by single-frequency bio-electrical impedance in COPD. Respir Med (2009) 1.49
Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am J Pathol (2007) 1.43
The last wish of a patient with end stage chronic obstructive pulmonary disease. BMJ (2008) 1.41
Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer (2007) 1.33
Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax (2007) 1.32
Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med (2010) 1.30
Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc (2011) 1.28
Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol (2010) 1.28
In situ detection of S-glutathionylated proteins following glutaredoxin-1 catalyzed cysteine derivatization. Biochim Biophys Acta (2006) 1.27
Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model. Arterioscler Thromb Vasc Biol (2007) 1.26
Modulation of glutaredoxin-1 expression in a mouse model of allergic airway disease. Am J Respir Cell Mol Biol (2006) 1.25
The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms. J Vasc Surg (2010) 1.23
Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med (2011) 1.23
Expression of vascular endothelial growth factor, stromal cell-derived factor-1, and CXCR4 in human limb muscle with acute and chronic ischemia. Arterioscler Thromb Vasc Biol (2007) 1.22
Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. Am J Respir Crit Care Med (2014) 1.20
Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax (2013) 1.20
Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways. Am J Physiol Cell Physiol (2002) 1.19
Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med (2003) 1.18
Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med (2003) 1.17
Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol (2005) 1.17
Leptin and the proinflammatory state associated with human obesity. J Clin Endocrinol Metab (2004) 1.17
Body mass index modulates aromatic DNA adduct levels and their persistence in smokers. Cancer Epidemiol Biomarkers Prev (2002) 1.16
Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.16
Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res (2007) 1.16
Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD (2006) 1.15
Herpes simplex virus load in bronchoalveolar lavage fluid is related to poor outcome in critically ill patients. Intensive Care Med (2008) 1.14
Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults. PLoS Negl Trop Dis (2012) 1.14
Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-alpha and preserves gut barrier function early after hemorrhagic shock. Shock (2004) 1.13
Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood (2002) 1.13
Increased systemic inflammation is a risk factor for COPD exacerbations. Chest (2008) 1.12
Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest (2003) 1.12
Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol (2008) 1.12
Bloodstream infection among adults in Phnom Penh, Cambodia: key pathogens and resistance patterns. PLoS One (2013) 1.12
Integration of pulmonary rehabilitation in COPD. Lancet (2008) 1.11
Nordic walking improves daily physical activities in COPD: a randomised controlled trial. Respir Res (2010) 1.11
Strain-specific effects of probiotics on gut barrier integrity following hemorrhagic shock. Infect Immun (2005) 1.10
Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol (2004) 1.10
Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease. Ann Med (2012) 1.09
Bloodstream infections in south and southeast Asia. Lancet Infect Dis (2013) 1.08
Symptoms of anxiety and depression in COPD patients entering pulmonary rehabilitation. Chron Respir Dis (2010) 1.08
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res (2002) 1.08
Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg (2009) 1.07
The metabolic response during resistance training and neuromuscular electrical stimulation (NMES) in patients with COPD, a pilot study. Respir Med (2008) 1.06
IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet (2009) 1.06
Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem (2006) 1.05
Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. J Palliat Med (2011) 1.05
Horizontal transfer of segments of the 16S rRNA genes between species of the Streptococcus anginosus group. J Bacteriol (2003) 1.04
Myeloperoxidase (MPO) -463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Myeloperoxidase deficiency attenuates lipopolysaccharide-induced acute lung inflammation and subsequent cytokine and chemokine production. J Immunol (2009) 1.04
Differences in walking pattern during 6-min walk test between patients with COPD and healthy subjects. PLoS One (2012) 1.04
Effect of 'activity monitor-based' counseling on physical activity and health-related outcomes in patients with chronic diseases: A systematic review and meta-analysis. Ann Med (2013) 1.04
A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest (2003) 1.03
Leptin modulates innate and adaptive immune cell recruitment after cigarette smoke exposure in mice. J Immunol (2010) 1.03
Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): a pivotal role of leptin. Respir Med (2011) 1.03
Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am J Physiol Renal Physiol (2007) 1.03
Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr (2002) 1.02
α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest (2010) 1.02
Task-related oxygen uptake during domestic activities of daily life in patients with COPD and healthy elderly subjects. Chest (2011) 1.02
Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component. Respir Med (2009) 1.02
Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol (2006) 1.01
Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006. J Travel Med (2008) 1.01
Supplementation of soy protein with branched-chain amino acids alters protein metabolism in healthy elderly and even more in patients with chronic obstructive pulmonary disease. Am J Clin Nutr (2007) 1.00
Limb muscle dysfunction in COPD: effects of muscle wasting and exercise training. Med Sci Sports Exerc (2005) 1.00